Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 7/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 3/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11686324 | 0.81 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA1GABRA3 | |
| SCHEMBL6870712 | 0.72 | GABRG2 (0.61) | GABRG2GABRB3GABRA5ALDH1A1 | |
| SCHEMBL11916094 | 0.69 | TTR (0.53) | GABRG2GABRB3GABRA5GABRA1CCKBR | |
| SCHEMBL6299894 | 0.69 | GABRP (0.46) | GABRG2GABRB3GABRA5GABRA1CCKBR | |
| SCHEMBL8054672 | 0.65 | TTR (0.52) | GABRG2GABRB3GABRA5GABRA1CCKBR | |
| SCHEMBL14075304 | 0.65 | TTR (0.47) | GABRG2GABRB3GABRA5GABRA1CCKBR | |
| SCHEMBL21761316 | 0.64 | BRPF1 (0.48) | GABRG2GABRB3GABRA5GABRA1CCKBR | |
| SCHEMBL7086781 | 0.64 | TTR (0.46) | GABRG2GABRB3GABRA5GABRA1CCKBR | |
| SCHEMBL4994391 | 0.63 | KMT2A (0.53) | GABRG2GABRB3GABRA5GABRA1CCKBR | |
| SCHEMBL1368138 | 0.63 | GABRA1 (0.63) | GABRG2GABRB3GABRA5GABRA1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838455-B2 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2005-01-04 | — | — | US | disclosed |
| EP-1093372-A4 | CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARM INC (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6696438-B2 | AMYLOID PRECURSOR PROTEIN ANTAGONISTS, 3-((N'-(3-PYRIDINOYL)-L -ALANINYL)-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO-2H-3-BENZAZEPIN-2-ONE, USED FOR PROPHYLAXIS OF NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030162768-A1 | Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | AUDIA JAMES E (US) | 2003-08-28 | — | — | US | disclosed |
| US-20030149022-A1 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | AUDIA JAMES E (US) | 2003-08-07 | — | — | US | disclosed |
| US-6552013-B1 | For therapy of Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| US-6528505-B1 | Treating Alzheimer's disease;5-(S)-(N'-(L-prolyl)-L-alaninyl)-amino-7-methyl-5,7-di hydro-6H- dibenz(b,d)azepin-one | ELAN PHARMACEUTICALS, INC. | 2003-03-04 | — | — | US | disclosed |
| EP-1093372-A1 | CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 2001-04-25 | — | — | EP | disclosed |
| EP-1089977-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999066934-A1 | CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067219-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162768-A1 | Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, IAPP, BACE1 | GABRG2 1473/4885GABRB3 942/4885GABRA5 1119/4885 |
| US-20030149022-A1 | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | APP, IAPP, BACE1 | GABRG2 2708/4885GABRB3 1654/4885GABRA5 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.